TRT in primary care: what NPs aren't always telling you

What's this video probably claiming?

A nurse practitioner posting under #NPtok with a TRT-adjacent caption about "what nobody warned you about in primary care" is almost certainly walking viewers through the clinical realities of prescribing testosterone in an outpatient setting. That framing, combined with the #HealthcareReality hashtag, suggests the creator is positioning themselves as a candid insider sharing things patients or even junior clinicians don't hear. Common territory for this kind of content: surprise findings on labs, the bureaucratic friction of getting TRT approved, the gap between how hormone optimization is marketed online versus how it actually plays out in a clinic chart. It may also touch on the volume of men self-diagnosing low testosterone based on symptom checklists they found on Reddit, then arriving expecting a prescription. That's a real and growing phenomenon in primary care, and it's worth examining what the evidence actually supports before the transcript confirms exactly what's being said here.

What does the science actually show?

Hypogonadism diagnosis requires more than a symptom score. The American Urological Association and Endocrine Society both require two fasting morning total testosterone measurements below 300 ng/dL, paired with clinical symptoms, before initiating therapy. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism (Rosenthal et al.) found that roughly 25% of men who self-reported low-T symptoms had total testosterone levels within normal reference ranges. Meanwhile, the TRAVERSE trial, published in NEJM in 2023 (Lincoff et al.), followed 5,246 men with hypogonadism and cardiovascular risk over approximately 33 months and found testosterone replacement did not significantly increase major adverse cardiac events compared to placebo, which partially resolved older safety fears, but also showed a statistically significant increase in atrial fibrillation, pulmonary embolism, and acute kidney injury in the treatment arm. That is the kind of nuanced data a rigorous primary care provider should be discussing with every patient, and that most social media TRT content quietly buries.

Where does the social media noise diverge from clinical reality?

TikTok's TRT ecosystem has a serious dose-reality problem. Creators, including some with clinical credentials, routinely discuss testosterone cypionate protocols in ranges of 150-200 mg per week framed as standard care. Clinical trials establishing efficacy for hypogonadism, including the Testosterone Trials (TTrials, NEJM 2016, Snyder et al.), used doses titrated to produce mid-normal physiologic levels, roughly 400-700 ng/dL total testosterone, not supraphysiologic targets. The "optimization" framing, where the goal is pushing levels to the top quartile of normal or beyond, is not supported by comparative efficacy data and carries real hematocrit, erythrocytosis, and lipid risks. The 2023 TRAVERSE data showed hematocrit exceeding 54% in a meaningful subset of the treatment arm. Primary care NPs and physicians working within a regulated system are navigating real liability and real clinical guidelines. A viral TikTok framing this as "what nobody told you" may be doing useful work or may be muddying those lines further. The transcript will tell us which.

What should you actually know?

If you're a patient watching content like this, here is the actual baseline. Testosterone levels fluctuate across the day, across seasons, and with sleep deprivation, obesity, and acute illness. A single low reading is not a diagnosis. You need two confirmed low fasting morning draws, a luteinizing hormone level to distinguish primary from secondary hypogonadism, and a proper symptom evaluation using something like the Androgen Deficiency in Aging Males (ADAM) questionnaire as a starting point, not an endpoint. Fertility implications are real: exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, often reducing sperm production significantly within 3-6 months of initiation (Gonzalez et al., 2004, Journal of Urology). If you're under 40 and considering TRT, that conversation needs to happen explicitly. A regulated telehealth provider should be running labs, reviewing history, and revisiting your levels at 3 and 6 months. Anyone skipping that process, online or in person, is not practicing evidence-based medicine regardless of what their follower count says.